Myeloproliferative Disorders

Momelotinib, a small-molecule oral inhibitor of the JAK1/JAK2 kinases was investigated in the phase 3 MOMENTUM study in patients with anaemic myelofibrosis (ClinicalTrials.gov Identifier: NCT04173494). touchHAEMATOLOGY were delighted to talk with Dr. Srdan Verstovsek (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) to discuss the mechanism of action of momelotinib, the findings […]

Myelofibrosis is a myeloproliferative disorder that leads to severe anaemia and splenomegaly, there is an unmet need for targeting anaemia in the current treatment options for myelofibrosis. In this touchHAEMATOLOGY interview, we spoke with Dr. Srdan Verstovsek (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) around the main challenges of managing myelofibrosis-related […]

Dr John Mascarenhas (Icahn School of Medicine at Mount Sinai, New York, NY, USA)  discusses pacritinib in the potential treatment of myelofibrosis and severe thrombocytopenia. Treatment options for myelofibrosis and severe thrombocytopenia are restricted due to high occurrences of JAK inhibitor-related thrombocytopenia. The abstract entitled ‘PACIFICA: A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician’s […]